Cancer Drug Developer Syndax Prices $53M IPO Below Range
Cancer immunotherapy company Syndax Pharmaceuticals Inc. priced a $52.8 million initial public offering below range late Wednesday, while a blank check company raised $39 million to pursue acquisitions in information technology,...To view the full article, register now.
Already a subscriber? Click here to view full article